OVERVIEW

Ipamorelin is a synthetic growth hormone–releasing peptide (GHRP) that selectively stimulates the release of growth hormone (GH) from the anterior pituitary gland. It functions by binding to the ghrelin (GHS-R1a) receptor, mimicking the action of the natural hunger hormone ghrelin. Unlike some earlier GHRPs, Ipamorelin is often described in research as having a more targeted profile, with minimal reported impact on cortisol and prolactin levels when compared under similar conditions. This selectivity has made it a compound of interest in laboratory studies examining anabolic signaling, tissue repair mechanisms, and endocrine regulation. By encouraging endogenous GH release rather than supplying synthetic growth hormone directly, Ipamorelin works within the body’s natural hormonal pathways.

In experimental settings, Ipamorelin has been explored for its potential influence on muscle protein synthesis, recovery processes, sleep quality, and metabolic activity. Growth hormone plays a central role in cellular repair, body composition, and overall metabolic balance, which explains the scientific interest surrounding this peptide. Because it stimulates the body’s own GH pulses, researchers often evaluate timing and dosage strategies to align with natural circadian rhythms. Although widely discussed in research and performance contexts, Ipamorelin is generally categorized as a research compound and is not broadly approved for routine therapeutic use outside controlled clinical investigation.